A detailed history of Wallace Advisory Group, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Wallace Advisory Group, LLC holds 6,104 shares of BMY stock, worth $260,274. This represents 0.24% of its overall portfolio holdings.

Number of Shares
6,104
Previous 5,154 18.43%
Holding current value
$260,274
Previous $299 Million 4.7%
% of portfolio
0.24%
Previous 0.23%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 12, 2024

BUY
$47.98 - $54.4 $45,581 - $51,680
950 Added 18.43%
6,104 $313 Million
Q4 2023

Jan 08, 2024

SELL
$48.48 - $57.85 $24,918 - $29,734
-514 Reduced 9.07%
5,154 $299 Million
Q3 2023

Oct 05, 2023

SELL
$57.89 - $64.73 $9,957 - $11,133
-172 Reduced 2.95%
5,668 $362 Million
Q1 2023

May 10, 2023

BUY
$65.71 - $74.53 $9,593 - $10,881
146 Added 2.56%
5,840 $405 Million
Q4 2022

Feb 21, 2023

BUY
$68.48 - $81.09 $389,925 - $461,726
5,694 New
5,694 $410 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $90.7B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Wallace Advisory Group, LLC Portfolio

Follow Wallace Advisory Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wallace Advisory Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wallace Advisory Group, LLC with notifications on news.